United States: USPTO Finds Suregene Personalized Medicine Treatment Unpatentable Under Mayo

In  Ex Parte Timothy, the USPTO Patent Trial and Appeal Board (PTAB) affirmed the Examiner's rejection of personalized medicine treatment claims. This decision highlights the PTAB's willingness to invalidate claims that it finds similar to the claims at issue in Mayo. It also underscores the need for Congressional action to incentivize and protect investments in this important frontier of health care.

The Personalized Medicine Treatment Claims

The decision was rendered in U.S. patent application 13/269,365, assigned to SureGene LLC. According to the background section of the application, in the treatment of psychotic disorders, "there are individual differences in response to specific drugs based on differences in drug pharmacology and metabolism, combined with genetic differences between patients." Also according to the application, "[t]here are currently no proven ways to identify which antipsychotic drug is optimal for a given patient. Thus, patients switch from one drug to another when response is not considered to be adequate or side effects are intolerable." Indeed, "[o]n average, each patient may change medications three times for finding one that works."

The application describes the invention as being "in part based on the finding that a genetic signature, which the inventors refer to as the Olanzapine Poor Response Predictor (OPRP), is a biomarker that can be used for selecting a more appropriate antipsychotic treatment plan for that particular subject. For example, the inventors have discovered that patients that are OPRP negative respond better than patients that are OPRP positive when treated with olanzapine, clozapine, or quetiapine."

Claim 1 was identified as representative:

1. A method for treating a human subject having or suspected of having a psychotic disorder, comprising:
a) selecting a subject having or suspected of having a psychotic disorder and who has been determined to
have the OPRP genetic signature, wherein the OPRP genetic signature is defined as a genotype comprising a homozygous genotype for the T allele at rs11960832 and either a homozygous or heterozygous genotype for the T allele at rs7975477; and
b) treating the subject that was determined to have the OPRP signature with an antipsychotic treatment other than clozapine or quetiapine.

The PTAB Decision

The PTAB summarized the § 101 rejection on appeal:

The Examiner has rejected claims 1-10 as being directed to patent-ineligible subject matter. The Examiner finds that, under the standard set out in Mayo Collaborative Services v. Prometheus Labs., Inc., 566 U.S. 66 (2012), "the claims inform a relevant audience about certain laws of nature. The additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community. The additional steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately." (Final Action 5.)

The Examiner also had found:

  • the correlation between the OPRP genetic signature and response to clozapine or quetiapine treatment is a "law of nature" under Mayo
  • the "selecting" is not sufficient to transform the claim into eligible subject matter
  • the "treatment" step did not distinguish the claims from Mayo, because the claims at issue in that case also were directed to a method of treatment.

The PTAB agreed, and set forth the claims from Mayo in its decision:

  1. A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:
    (a) administering a drug providing 6–thioguanine to a subject having said immune-mediated gastrointestinal disorder; and
    (b) determining the level of 6–thioguanine in said subject having said immune-mediated gastrointestinal
    disorder,
    wherein levels of 6–thioguanine below or above certain thresholds indicate a need to increase or decrease, respectively, the amount of drug being administered.

The PTAB drew several analogies to the Mayo decision, including:

The Court [in Mayo] concluded that "[a]nyone who wants to make use of these laws must first administer a thiopurine drug and measure the resulting metabolite concentrations, and so the combination amounts to nothing significantly more than an instruction to doctors to apply the applicable laws when treating their patients." .... Similarly here, anyone who wants to make use of the natural law–the relationship between the OPRP genetic signature and the lack of efficacy of clozapine or quetiapine –must first determine whether a given patient has the OPRP genetic signature before determining which antipsychotic medication to treat them with. Thus, claim 1 amounts to nothing significantly more than an instruction to doctors to apply the applicable law when treating their patients.

The PTAB rejected the argument that the claim should be eligible as a new use of a known drug, because "the treatment of schizophrenic patients with antipsychotic drugs other than clozapine or quetiapine does not represent a new use for the known antipsychotic drugs." Thus, the PTAB did not give any weight to the patient selection steps when determining that the claim related to a known use of a known drug.

The PTAB also rejected the argument that the claim should be eligible by analogy to the USPTO's amazonic acid example, asserting that "the cited exemplary claims address analysis of a different class of inventions that have been held to be patent-ineligible," i.e., natural products that are analyzed under Myriad. The PTAB emphasized, as it has in other decisions, that it is not bound by the USPTO's Subject Matter Eligibility Guidelines.

Inconsistency Won't Incentivize Investment

Subject matter eligibility was a hot topic at the IPO Annual Meeting last week. Even though panelists didn't agree on the best way to address the recent changes in this area of U.S. patent law, everyone agreed that predictability–the ability to know what is and what is not patentable–is essential to making sound business and investment decisions. In that context, it is striking that the PTAB relied on a 2012 Supreme Court decision (Mayo), even though SureGene had obtained several personalized medicine patents since that case was decided–including patents granted as recently as 2015.

The PTAB's unwillingness to adhere to the USPTO's Subject Matter Eligibility Guidelines also is disturbing, and makes the patent application process even more inconsistent and unpredictable. While the PTAB had grounds for distinguishing the "amazonic acid" claims, it did not address–or even expressly acknowledge–the diagnosing and treating claims of the "julitis" example, which are said to be eligible in an analysis that considers the contribution of the claimed "combination of steps," gives weight to the fact that the combination "is not routine and conventional," and finds "significantly more" in "ensur[ing] that patients who have julitis will be accurately diagnosed (due to the detection of JUL-1 in their plasma) and properly treated." An Examiner following these Guidelines could grant claims that an Examiner not following the guidelines would not, and the PTAB might uphold the Examiner who did not follow the guidelines!

Also a hot topic at the IPO Annual Meeting was possible legislative changes to § 101. While not all stakeholders agreed that Congressional action is needed to address issues facing computer and business method patents, most agreed that diagnostic methods and personalized medicine should be brought back into the realm of eligible subject matter, such as by legislation that would at least abrogate Mayo, if not Myriad.

On this point, it is important to keep in mind that SureGene's patent application at issue here was filed before the Supreme Court decision in Mayo. Thus, SureGene invested in this technology against a landscape where it would be patentable. How can we expect continued innovation in these fields without patent protection?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions